Denovium teams up with Primordial Genetics

Primordial Genetics, a synthetic biology company, and Denovium Inc., an artificial intelligence company, are collaborating to develop novel and more efficient enzymes for DNA synthesis to ultimately impact the diagnosis, prevention and treatment of human diseases, such as cancer, heart disease, HIV and genetic diseases, such as cystic fibrosis. The research and development project is supported through a grant by the National Human Genome Research Institute of the National Institutes of Health.

Posted by

Comments are closed.